Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(60%)
Results Posted
50%(1 trials)

Phase Distribution

Ph not_applicable
3
60%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Recruiting3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

recruiting360%
completed240%

Recent Activity

3 active trials
Showing 5 of 5
recruitingnot_applicable

Mental Stress Reactivity in Women With CMD

NCT05401630
recruiting

Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study

NCT05677880
recruiting

POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors

NCT04193956
completednot_applicable

Motherhood and Pelvic Health (MAP Study)

NCT02512016
completednot_applicable

Assessment of Novel Respiratory Protective Devices in Healthcare

NCT02082158

Clinical Trials (5)

Showing 5 of 5 trials
NCT05401630Not Applicable

Mental Stress Reactivity in Women With CMD

Recruiting
NCT05677880

Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study

Recruiting
NCT04193956

POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors

Recruiting
NCT02512016Not Applicable

Motherhood and Pelvic Health (MAP Study)

Completed
NCT02082158Not Applicable

Assessment of Novel Respiratory Protective Devices in Healthcare

Completed

All 5 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
5